Replies to post #52998 on Grapefruit USA Inc (GPFT)

[stockmasterflash]

Because just as IMGG did previously

Dane Medley is VASTLY exaggerating where they are in the process in order to raise funds from the gullible public. Compare the bold and underlined to where you believed IGNG to be based on their previous statements

***

Imaging3, Inc. (OTCQB: “IGNG”) Announces Execution of Consulting Service Agreement with Biologics Consulting Group, Inc.



Burbank, CA October 11, 2016 (Globe Newswire) Imaging3™, Inc. (the “Company”) (OTCQB: IGNG) announced today that on September 26, 2016 the Company signed a Consulting Services Agreement (the “Agreement”) with Biologics Consulting Group, Inc. of Alexandria, VA (“Biologics”), by which Biologics agrees to provide consulting services to manage the planning for and drafting of the Company’s 510K application for its Volumetric Imaging Scanner (“VIS”) for submission to the United States Food and Drug Administration (the “FDA”). On October 3, 2016, Biologics accepted the first work order (the “Work Order”) under the Agreement: a regulatory assessment of the Company’s VIS in preparation for the 510K submission.

The Company retained Biologics in 2011 to review the Company’s 510K submission of 2009 after it was denied by the FDA in March, 2010. After discussions to determine why the 2009 510K application was denied and whether the concerns that caused the FDA to issue such denial could be remedied in a new filing, Biologics and the Company determined that such matters could be addressed in a new, strategically prepared and detailed application which could support FDA approval. On September 8, 2011, with substantial research and preparation, Biologics submitted a Pre–IDE request to initiate the process of the new FDA application. This effort was thwarted by the financial issues which led to the Company’s bankruptcy filing in September, 2012.


Dane Medley, Chairman/CEO of Imaging3 commented, “We are very pleased that Biologics has agreed to continue the work it commenced in 2011 in connection with the FDA 510K application and approval process for the VIS, even after our arduous reorganization process. Having a strong team with their proven success rate lends undeniable credibility to our project. To have a truly best-in-class firm like Biologics as our quarterback as we prepare to approach the FDA with our 510K application engenders confidence in the Company’s management and investors. Having already entered into our previously announced agreement with Critech concerning validation of our proprietary software, this step with Biologics further builds momentum toward our goal of FDA approval of our first imaging device utilizing our technology.”


Norman W. Baylor, PhD, Biologics President & CEO stated, “We look forward to resuming our relationship with Imaging3 to assist them in preparing and navigating their 510K through the U.S. FDA.”